China gains ground in first-launched medicines as U.S. lead narrows

New research from the National Pharmaceutical Council finds China’s share of first-launched medicines surged over the past two decades while Europe’s declined, reshaping the global biopharmaceutical map. The U.S. still leads overall, but its advantage has weakened since the early 2000s.

Why it matters: - The findings point to a major shift in where new medicines reach patients first, a proxy for biopharmaceutical innovation leadership. - The U.S. remains No. 1 overall, but a narrower lead raises questions for policymakers, investors, and drug developers. - The study also highlights oncology as a key driver of China’s rise.

What happened: - The National Pharmaceutical Council published a new analysis in the peer-reviewed journal Therapeutic Innovation & Regulatory Science. - The study tracked first-launched medicines from 2004 through 2024 across global biopharmaceutical markets. - Researchers used Citeline’s PharmaProjects database to identify where small-molecule and biologic drugs launched first and the home countries of the companies that developed them. - A first launch means the first country where a medicine becomes commercially available.

The details: - Europe’s share of first launches fell from 26.7% in 2004 to 8.5% in 2024. - The share of first launches from European companies declined from 26.7% to 20.7% over the same period. - China’s share of first launches rose from 3.3% in 2004 to 28.7% in 2024. - China’s share of first launches in oncology grew from 8.3% to 56.1%. - The share of first launches from China-headquartered companies increased from 1.7% to 26.2%. - The U.S. accounted for the largest share of first launches over the full period at 43.1%. - The U.S. share of first launches fell from 45.9% in 2004 to 37.8% in 2024. - The share of first launches from U.S.-headquartered companies declined from 38.3% to 31.7%. - The study is descriptive and does not identify why these shifts happened. - The authors say biopharmaceutical leadership includes additional measures outside the scope of the study. - Prior reviews by the Government Accountability Office, the European Commission, and independent researchers have linked Europe’s decline in part to pricing and reimbursement policies. - The research expands on NPC’s February 2026 fact sheet, U.S. Biopharmaceutical Leadership Amidst Changing Price Regulation.

Between the lines: - The data suggest innovation activity is becoming more geographically dispersed, with China gaining share fast while Europe loses ground. - The results do not prove causation, but they strengthen the case that policy, market access, and reimbursement rules may influence where companies choose to launch first. - The U.S. still dominates, yet the trend line shows competitive pressure from China and continued erosion in Europe.

What's next: - NPC’s findings are likely to fuel more debate over how pricing, reimbursement, and innovation policy shape global drug development. - The study leaves open whether the same pattern will continue in the next two decades. - Further analysis could compare first launches with other measures of leadership, including R&D output, capital investment, and regulatory speed. - NPC says more information is available at npcnow.org and on its LinkedIn page and X account.